The Jenner Institute, University of Oxford, Oxford, UK.
Lancet Respir Med. 2019 Sep;7(9):810-819. doi: 10.1016/S2213-2600(19)30274-7. Epub 2019 Aug 12.
Tuberculosis kills more people than any other pathogen and the need for a universally effective vaccine has never been greater. An effective vaccine will be a key tool in achieving the targets set by WHO in the End TB Strategy. Tuberculosis vaccine development is difficult and slow. Substantial progress has been made in research and development of tuberculosis vaccines in the past 20 years, and two clinical trial results from 2018 provide reason for optimism. However, many challenges to the successful licensure and deployment of an effective tuberculosis vaccine remain. The development of new tools for vaccine evaluation might facilitate these processes, and continued collaborative working and sustained funding will be essential.
结核病的致死人数比其他任何病原体都多,因此现在比以往任何时候都更需要一种普遍有效的疫苗。有效的疫苗将是实现世卫组织《终止结核病战略》目标的关键工具。结核病疫苗的研发困难重重且进展缓慢。过去 20 年中,结核病疫苗的研发取得了重大进展,2018 年的两项临床试验结果令人乐观。但是,在成功获得有效结核病疫苗的许可和部署方面仍然存在诸多挑战。新的疫苗评估工具的开发可能会促进这些进程,持续的合作和持续的资金投入将是必不可少的。